secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zomedica Corp. (ZOMDF)
CIK:        0001684144
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001654954-26-004419
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zomedica Q1 revenue record $8.8M, up 35% YoY; net loss narrows to $4.5M
-----------------------------------------------------------------------

- Record Q1 revenue $8.8M, up 35% from $6.5M in Q1 2025; 21st straight quarter of YoY growth.
- Diagnostics segment revenue $1.0M, +73% YoY; Therapeutic Devices $5.8M flat; Development Services $2.0M.
- Net loss $4.5M vs $63.8M in prior year which included $55.8M impairment; Adjusted EBITDA loss improved 58% to $2.4M.
- Cash burn reduced 15% to $5.7M; liquidity $47.5M as of March 31, 2026.
- Launched TRUVIEW AI telepathology platform and announced collaboration with Boehringer Ingelheim for equine PPID testing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1684144/000165495426004419/0001654954-26-004419-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1684144/000165495426004419/zom_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-26-004419

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer